Across all three sensitivity analyses—(i) complete case analysis; (ii) EORA defined as individuals aged 70 years and older; and (iii) subgroup analysis of autoantibody positive RA patients (either RF or ACPA positive)—similar clinical outcomes and PROs were observed over time, and after 12 and 24 months of follow-up (Supplementary Tables S1–S6 and Figs S4–S12). The gene discussed is PRTN3; the disease is rheumatoid arthritis.